These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18335226)

  • 41. Clinical outcome of using ganirelix acetate versus a 4-day follicular phase leuprolide acetate protocol in unselected women undergoing in vitro fertilization.
    Posada MN; Vlahos NP; Jurema MW; Bracero NJ; Wallach EE; Garcia JE
    Fertil Steril; 2003 Jul; 80(1):103-10. PubMed ID: 12849810
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.
    Hosseini MA; Aleyasin A; Saeedi H; Mahdavi A
    J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Agonist "flare-up" versus antagonist in the management of poor responders undergoing in vitro fertilization treatment.
    Mohamed KA; Davies WA; Allsopp J; Lashen H
    Fertil Steril; 2005 Feb; 83(2):331-5. PubMed ID: 15705370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration.
    Lee TH; Wu MY; Chen HF; Chen MJ; Ho HN; Yang YS
    Fertil Steril; 2005 Jun; 83(6):1700-7. PubMed ID: 15950639
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Kalogeropoulou L; Papanikolaou E; Tarlatzis BC
    Fertil Steril; 2011 Feb; 95(2):558-62. PubMed ID: 20637457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle.
    Kummer NE; Weitzman VN; Benadiva CA; Schmidt DW; Engmann LL; Nulsen JC
    Fertil Steril; 2011 Jun; 95(8):2592-4. PubMed ID: 21292260
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of different stimulation protocols efficacy in poor responders undergoing IVF: a retrospective study.
    Madani T; Ashrafi M; Yeganeh LM
    Gynecol Endocrinol; 2012 Feb; 28(2):102-5. PubMed ID: 22263965
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
    Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative prospective study of 2 ovarian stimulation protocols in poor responders: effect on implantation rate and ongoing pregnancy.
    Merviel P; Cabry-Goubet R; Lourdel E; Devaux A; Belhadri-Mansouri N; Copin H; Benkhalifa M
    Reprod Health; 2015 May; 12():52. PubMed ID: 26025412
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization.
    Orvieto R; Zohav E; Scharf S; Rabinson J; Meltcer S; Anteby EY; Homburg R
    Gynecol Endocrinol; 2007 Feb; 23(2):72-5. PubMed ID: 17454155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results with GnRH antagonist protocols are equivalent to GnRH agonist protocols in comparable patient populations.
    Luna M; Vela G; McDonald CA; Copperman AB
    J Reprod Med; 2012; 57(3-4):123-8. PubMed ID: 22523871
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment with gonadotropin-releasing hormone (GnRH) antagonists in women suppressed with GnRH agonist may avoid cycle cancellation in patients at risk for ovarian hyperstimulation syndrome.
    Gustofson RL; Larsen FW; Bush MR; Segars JH
    Fertil Steril; 2006 Jan; 85(1):251-4. PubMed ID: 16412770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
    Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
    J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
    Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C
    Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modified natural cycle using GnRH antagonist can be an optional treatment in poor responders undergoing IVF.
    Elizur SE; Aslan D; Shulman A; Weisz B; Bider D; Dor J
    J Assist Reprod Genet; 2005 Feb; 22(2):75-9. PubMed ID: 15844732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follicular phase endocrine characteristics during ovarian stimulation and GnRH antagonist cotreatment for IVF: RCT comparing recFSH initiated on cycle day 2 or 5.
    Blockeel C; Sterrenburg MD; Broekmans FJ; Eijkemans MJ; Smitz J; Devroey P; Fauser BC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1122-8. PubMed ID: 21307142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years.
    D'Amato G; Caroppo E; Pasquadibisceglie A; Carone D; Vitti A; Vizziello GM
    Fertil Steril; 2004 Jun; 81(6):1572-7. PubMed ID: 15193479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.